Targeting p31comet to Enhance Cisplatin-induced Cytotoxicity in Oral Squamous Cell Carcinoma Cells
Science Letters · 12.01.2024
DOI: 10.48797/sl.2024.121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Letters, erschienen am 12.01.2024. Verfasst von Silva und 5 weiteren Autor:innen.
Abstract (Originalsprache)
p31comet plays a crucial role in silencing the spindle assembly checkpoint during mitosis. This study aimed to investigate whether p31comet knockdown could enhance cisplatin-induced cytotoxicity in oral cancer cells. We assessed p31comet expression in oral squamous cell carcinoma (OSCC) cells and examined the impact of p31comet knockdown, cisplatin treatment, and their combination on OSCC cell viability and colony formation ability. Our findings indicated an upregulation of p31comet at both mRNA and protein levels in OSCC cells compared with non-cancer cells. Knockdown of p31comet amplified the inhibitory effects of cisplatin on OSCC cell viability and colony formation, particularly in cells more resistant to cisplatin. This suggests that exploring the combination of p31comet inhibition and cisplatin could be a potentially promising strategy to enhance sensitivity of oral cancer cells to cisplatin.
Schlagwörter
Zitieren
APA
Silva, A., P. M., Henriques, A. C., Silva, J. P., Pinto, B. F., & Bousbaa, H. (2024). Targeting p31comet to Enhance Cisplatin-induced Cytotoxicity in Oral Squamous Cell Carcinoma Cells. Science Letters. https://doi.org/10.48797/sl.2024.121
Vancouver
Silva, A. PM, Henriques AC, Silva JP, Pinto BF, Bousbaa H. Targeting p31comet to Enhance Cisplatin-induced Cytotoxicity in Oral Squamous Cell Carcinoma Cells. Science Letters. 2024. doi:10.48797/sl.2024.121
BibTeX
@article{Silva2024,
author = {Silva and A., Patricia M. and Henriques, Ana C. and Silva, João P.N. and Pinto, Bárbara Fernandes and Bousbaa, Hassan},
title = {Targeting p31comet to Enhance Cisplatin-induced Cytotoxicity in Oral Squamous Cell Carcinoma Cells},
journal = {Science Letters},
year = {2024},
doi = {10.48797/sl.2024.121}
}
EUVIMED